Latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Bill addressing patient access and drug pricing in American healthcare system.
The problem
Americans face high prescription drug costs and limited access to medications. Healthcare affordability remains a significant concern for patients and families.
The proposal
The bill proposes changes to drug pricing, patient access programs, and healthcare delivery. Specific provisions await committee review and formal bill text release.
The impact
Patients, pharmaceutical companies, insurers, and healthcare providers would be affected. Changes could impact drug prices, treatment availability, and healthcare costs.
The bill title suggests focus on patient-first approaches to drug pricing. Lower medication costs could help Americans afford necessary treatments.
Policies aimed at patients first could expand access to medications. More Americans might afford and receive needed prescriptions.
Reforms may increase clarity about drug pricing and costs. Better information helps patients make informed healthcare decisions.
Price controls or restrictions could reduce drug company profits. Lower revenues might decrease investment in developing new medicines.
Changes to drug pricing and access affect insurance company operations. Insurers may need to adjust coverage and premium structures.
Healthcare system changes require coordination across many organizations. Unclear how providers, insurers, and pharmacies will adapt.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.